Clinical characteristics, cytogenetics, and molecular mutations of 275 patients with CMML
| . | Total cohort (n = 275) . | SRSF2mut (n = 129; 47%) . | SRSF2wt (n = 146; 53%) . | P . |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Male/female (ratio) | 189/86 (2.2) | 91/38 (2.4) | 98/48 (2.0) | NS |
| CMML-1, n (%) | 193 (70) | 91 (47) | 102 (53) | NS |
| CMML-2, n (%) | 82 (30) | 38 (46) | 44 (54) | NS |
| Median age, y (range) | 72.8 (21.9-93.3) | 73.6 (49.9-89.5) | 71.5 (21.9-93.3) | .011 |
| Median WBC count, × 103/μL, (range; n = 247) | 15.3 (0.9-160.0) | 17.4 (2.2-113.2) | 12.9 (0.9-160.0) | NS |
| Median platelet count, × 103/μL (range; n = 227) | 90.0 (3.0-1385) | 80.5 (3.0-1119) | 105.0 (5.0-1385) | NS |
| Median Hb level, g/dL (range; n = 226) | 11.0 (4.0-18.2) | 11.3 (6.0-15.5) | 10.2 (4.0-18.2) | .006 |
| Cytogenetics (n = 269) | ||||
| Normal karyotype, n (%) | 190 (71) | 101 (53) | 89 (47) | .001 |
| Aberrant karyotype, n (%) | 79 (29) | 24 (30) | 55 (70) | |
| Trisomy 8, n (%) | 26 (33) | 9 (35) | 17 (65) | NS |
| Y-chromosome, n (%) | 13 (17) | 2 (15) | 11 (85) | NS |
| Chromosome 7 aberration, n (%) | 9 (11) | 4 (44) | 5 (56) | NS |
| Complex, n (%) | 4 (5) | 1 (25) | 3 (75) | |
| All other, n (%) | 27 (34) | 8 (30) | 19 (70) | |
| Molecular mutations | ||||
| ASXL1; (n = 261) | NS | |||
| Mutated, n (%) | 115 (44) | 56 (49) | 59 (51) | |
| Wild-type, n (%) | 146 (56) | 68 (47) | 78 (53) | |
| CBL (n = 274) | NS | |||
| Mutated, n (%) | 51 (19) | 27 (53) | 24 (47) | |
| Wild-type, n (%) | 223 (81) | 101 (45) | 122 (55) | |
| EZH2 (n = 208) | < .001 | |||
| Mutated, n (%) | 20 (10) | 1 (5) | 19 (95) | |
| Wild-type, n (%) | 188 (90) | 106 (56) | 82 (44) | |
| JAK2V617F (n = 275) | NS | |||
| Mutated, n (%) | 18 (7) | 9 (50) | 9 (50) | |
| Wild-type, n (%) | 257 (93) | 120 (47) | 137 (53) | |
| KRAS (n = 266) | NS | |||
| Mutated, n (%) | 28 (11) | 10 (36) | 18 (64) | |
| Wild-type, n (%) | 238 (89) | 117 (49) | 121 (51) | |
| NRAS (n = 273) | NS | |||
| Mutated, n (%) | 43 (16) | 17 (40) | 26 (60) | |
| Wild-type, n (%) | 230 (84) | 111 (48) | 119 (52) | |
| RUNX1 (n = 274) | NS | |||
| Mutated, n (%) | 61 (22) | 34 (56) | 27 (44) | |
| Wild-type, n (%) | 213 (78) | 94 (44) | 119 (56) | |
| TET2 (n = 160) | .001 | |||
| Mutated, n (%) | 97 (61) | 60 (62) | 37 (38) | |
| Wild-type, n (%) | 63 (39) | 22 (35) | 41 (65) |
| . | Total cohort (n = 275) . | SRSF2mut (n = 129; 47%) . | SRSF2wt (n = 146; 53%) . | P . |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Male/female (ratio) | 189/86 (2.2) | 91/38 (2.4) | 98/48 (2.0) | NS |
| CMML-1, n (%) | 193 (70) | 91 (47) | 102 (53) | NS |
| CMML-2, n (%) | 82 (30) | 38 (46) | 44 (54) | NS |
| Median age, y (range) | 72.8 (21.9-93.3) | 73.6 (49.9-89.5) | 71.5 (21.9-93.3) | .011 |
| Median WBC count, × 103/μL, (range; n = 247) | 15.3 (0.9-160.0) | 17.4 (2.2-113.2) | 12.9 (0.9-160.0) | NS |
| Median platelet count, × 103/μL (range; n = 227) | 90.0 (3.0-1385) | 80.5 (3.0-1119) | 105.0 (5.0-1385) | NS |
| Median Hb level, g/dL (range; n = 226) | 11.0 (4.0-18.2) | 11.3 (6.0-15.5) | 10.2 (4.0-18.2) | .006 |
| Cytogenetics (n = 269) | ||||
| Normal karyotype, n (%) | 190 (71) | 101 (53) | 89 (47) | .001 |
| Aberrant karyotype, n (%) | 79 (29) | 24 (30) | 55 (70) | |
| Trisomy 8, n (%) | 26 (33) | 9 (35) | 17 (65) | NS |
| Y-chromosome, n (%) | 13 (17) | 2 (15) | 11 (85) | NS |
| Chromosome 7 aberration, n (%) | 9 (11) | 4 (44) | 5 (56) | NS |
| Complex, n (%) | 4 (5) | 1 (25) | 3 (75) | |
| All other, n (%) | 27 (34) | 8 (30) | 19 (70) | |
| Molecular mutations | ||||
| ASXL1; (n = 261) | NS | |||
| Mutated, n (%) | 115 (44) | 56 (49) | 59 (51) | |
| Wild-type, n (%) | 146 (56) | 68 (47) | 78 (53) | |
| CBL (n = 274) | NS | |||
| Mutated, n (%) | 51 (19) | 27 (53) | 24 (47) | |
| Wild-type, n (%) | 223 (81) | 101 (45) | 122 (55) | |
| EZH2 (n = 208) | < .001 | |||
| Mutated, n (%) | 20 (10) | 1 (5) | 19 (95) | |
| Wild-type, n (%) | 188 (90) | 106 (56) | 82 (44) | |
| JAK2V617F (n = 275) | NS | |||
| Mutated, n (%) | 18 (7) | 9 (50) | 9 (50) | |
| Wild-type, n (%) | 257 (93) | 120 (47) | 137 (53) | |
| KRAS (n = 266) | NS | |||
| Mutated, n (%) | 28 (11) | 10 (36) | 18 (64) | |
| Wild-type, n (%) | 238 (89) | 117 (49) | 121 (51) | |
| NRAS (n = 273) | NS | |||
| Mutated, n (%) | 43 (16) | 17 (40) | 26 (60) | |
| Wild-type, n (%) | 230 (84) | 111 (48) | 119 (52) | |
| RUNX1 (n = 274) | NS | |||
| Mutated, n (%) | 61 (22) | 34 (56) | 27 (44) | |
| Wild-type, n (%) | 213 (78) | 94 (44) | 119 (56) | |
| TET2 (n = 160) | .001 | |||
| Mutated, n (%) | 97 (61) | 60 (62) | 37 (38) | |
| Wild-type, n (%) | 63 (39) | 22 (35) | 41 (65) |
P values are given for significant differences.
Hb indicates hemoglobin.